Viral and Nonviral Engineering of Natural Killer Cells as Emerging Adoptive Cancer Immunotherapies

Table 3

Registered worldwide clinical trials with genetically engineered NK cells.

Target	Sponsor and Clinicaltrials.gov identifier	Disease	Phase	Cell type
CD7—TCRζ, CD28, and 4-1BB	PersonGen BioTherapeutics, Suzhou, Jiangsu, China; NCT02742727	Leukemia and lymphoma	Phase I/II	NK-92 cells
CD19/TCRζ/CD28 and 4-1BB	PersonGen BioTherapeutics, Suzhou, Jiangsu, China; NCT02892695	Relapsed/refractory ALL, CLL, FL, BCL, DLBCL	Phase I/II	NK-92 cells
CD33/CD28/4-1BB	PersonGen BioTherapeutics, Suzhou, Jiangsu, China; NCT02944162	Relapsed/refractory ALL	Phase I/II	NK-92 cells
MUC1	PersonGen BioTherapeutics, Suzhou, Jiangsu, China; NCT02839954	MUC1^+ solid tumors	Phase I/II	Peripheral blood NK cells
CD19/4-1BB/CD18/iCasp9/IL-15	MD Anderson Cancer Center, Houston, TX, USA; NCT03056339	B cell malignancies	Phase I/II	Cord blood-derived NK cells
CD19/4-1BB/CD3ζ	National University of Singapore, Singapore; NCT01974479	B-cell ALL	Phase I	Peripheral blood NK cells
CD19/4-1BB/CD3ζ	St. Jude’s Children Research Hospital, Memphis, TN, USA; NCT00995137	ALL	Phase I	Peripheral blood NK cells
NKG2D	The Third Affiliated Hospital of Guangzhou Medical University; NCT03415100	Metastatic solid tumors	Phase I	Peripheral blood NK cells

ALL: acute lymphoblastic leukemia; CLL: chronic lymphocytic leukemia; FL: follicular lymphoma; BCL: B cell lymphoma; MCL: mantle cell lymphoma; DLBCL: diffuse large cell lymphoma; AML: acute myeloid leukemia; NHL: non-Hodgkin Lymphoma.